try the craigslist app » Android iOS



Tumors of the Central Nervous System (CNS) Research at NIH – GM (Bethesda)

9000 Rockville Pike

(google map)

Immune Checkpoint Inhibitor Nivolumab for Patients with Rare CNS Cancers

National Cancer Institute (NCI) researchers are conducting a study of patients with rare central nervous system (CNS) tumors. More than 130 primary rare CNS (brain or spine) tumors have been identified. Most affect less than 2,000 people in the United States each year. This study will test whether stimulating the immune system using the drug nivolumab can shrink select rare brain or spine tumors or increase the time it takes for them to grow or spread.

What the study involves:
Full physical and neurological examination
Patient questionnaire about health and symptoms
Series of MRIs and neurological function tests
Study of tumor tissue from prior surgeries
Receive drug nivolumab for up to 20 treatments over 64 weeks
Study of tumor tissue from prior surgeries
Monitoring for up to 5 years after treatment

You can participate if you:
Are age 18 or older
Do not have hepatitis
Are not pregnant or breastfeeding
Are diagnosed with CNS tumors that have returned

Tumor Types Include:
Atypical Teratoid Rhabdoid Tumor (ATRT), Choroid Plexus Tumors (Carcinoma, Papilloma, Atypical Papilloma), Ependymoma, Gliomatosis Cerebri, Gliosarcoma or Primary CNS Sarcoma, Histone Mutated Glioma, Medulloblastoma, Meningioma (High Grade), Pineal Region Tumors (Pineoblastoma, Pineocytoma, PTID, PTPR), Pleomorphic Xanthoastrocytoma (PXA) and Anaplastic Pleomorphic Xanthoastrocytoma (APXA) and Primitive Neuroectodermal Tumors (PNET)

You can participate in this study by visiting the NIH for a clinical assessment.

The NIH Clinical Center, America’s Research Hospital located in Bethesda, MD
Metro red line (Medical Center stop)
For more information:
NIH Clinical Center Office of Patient Recruitment
Se habla español
Refer to NIH Study: 17-C-0102
  • do NOT contact me with unsolicited services or offers

post id: 7094920625



best of [?]